Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET

Company Participants

Lisa Ricciardi - President & CEO
John Doyle - CFO
Tony Caggiano - CMO & Head of R&D
Mike Moyer - IR, LifeSci Advisors

Conference Call Participants

Charles Duncan - Cantor Fitzgerald
Jay Olson - Oppenheimer
Mayank Mamtani - B. Riley Securities

Operator

Hello, everyone, and welcome to Cognition Therapeutics Fourth Quarter 2023 Earnings Call. Please note that this call is being recorded. I’d now like to hand over to our first speaker for today, Mike Moyer. Please go ahead.

Mike Moyer

Thank you, Operator, and good morning, everyone. Welcome to the Cognition Therapeutics fourth quarter and year-end 2023 results conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer, John Doyle, Chief Financial Officer, and Dr. Tony Caggiano, Chief Medical Officer.

This morning, the company issued a press release detailing its 2023 fourth quarter and year-end results. We encourage everyone to read this morning’s press release, as well as Cognition’s annual report on Form 10-K, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company’s website and will be archived for 30 days.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company’s business. These forward-looking statements are qualified by the cautionary statements contained in Cognition’s press release and SEC filings, including its quarterly report on Form 10-Q and previous filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Cognition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.

With that, I would now like to hand the call over to Lisa Ricciardi.

Lisa Ricciardi

Mike, thank you. Good morning, everyone. Welcome to Cognition Therapeutics earnings conference call covering our 2023 results and highlights from recent weeks. On today's call, John Doyle and I will share prepared remarks on the company's progress, and then we'll be joined by Dr. Tony Caggiano, our Chief Medical Officer and Head of R&D, to take your questions. Cognition's focus is the development of innovative, orally available drug candidates targeting age-related degenerative diseases of the central nervous system and retina. Our current clinical programs build on our expertise in the sigma-2 receptor, which regulates cellular functions disrupted by neurodegenerative diseases. Our drug candidate - our leading drug candidate is currently in the clinic being tested for Alzheimer's disease and dementia with Lewy bodies, also referred to as DLB. Within Alzheimer's disease, we're studying both early-stage patients and patients with mild to moderate disease. We're also studying CT1812 in geographic atrophy second to dry age-related AMD or dry AMD as it is known. Modulating the sigma-2 receptor complex with a brain penetrant small molecule drug candidate is a unique approach, differentiated from other companies developing treatments in both neurodegenerative and ophthalmology diseases.